AZTherapies, Inc. is a private, clinical-stage biopharmaceutical company headquartered in Boston, MA. It focuses on developing innovative treatments for neurodegenerative diseases, particularly Alzheimer's disease. The company's approach targets critical underlying mechanisms such as neuroinflammation and mitochondrial dysfunction. Its lead candidate, ALZT-OP1, aimed to combine two reformulated existing drugs to address these pathways, though its Phase 3 COGNITE trial did not meet its primary endpoints in 2021. The company continues to explore therapeutic options in neurodegeneration.
The headquarters serves as the central location for corporate management, strategic planning, clinical development oversight, research collaborations, and administrative functions.
Located in a major office building in Boston's Financial District, providing access to a dense network of research institutions, talent, and potential partners. Specific architectural details of their suite are not publicly emphasized.
Likely fosters a focused, science-driven, and resilient work environment, characteristic of clinical-stage biotech companies. Emphasis would be on innovation, rigorous research, and addressing complex medical challenges in neurodegenerative diseases.
The Boston location provides strategic advantages, including proximity to world-class academic institutions, hospitals, a rich talent pool in life sciences, and a vibrant venture capital and investment community.
AZTherapies, Inc. is primarily based in the United States, with its operations centered at its Boston headquarters. While its clinical trials historically involved international sites to ensure diverse patient populations, its core R&D, strategic, and administrative functions are managed from the US. The company's therapeutic focus on Alzheimer's disease addresses a global health challenge.
60 State Street, Suite 700
Boston
MA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AZTherapies' leadership includes:
AZTherapies has been backed by several prominent investors over the years, including:
No major public announcements regarding executive hires or departures at AZTherapies, Inc. have been identified in the last 12 months. The company's leadership team appears to have remained consistent during this period.
Discover the tools AZTherapies uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
AZTherapies, Inc. likely uses a standard professional email format. A common pattern observed for companies of its profile is the first initial followed by the last name.
[first_initial][last]@aztherapies.com
Format
delmaleh@aztherapies.com
Example
70%
Success rate
PR Newswire • March 28, 2023
AZTherapies announced a publication in the Journal of Alzheimer's Disease detailing preclinical findings that support the multimodal mechanism of action for ALZT-OP1. The research suggests ALZT-OP1's potential to target neuroinflammation and amyloid-beta pathology, key factors in Alzheimer's disease progression....more
AZTherapies, Inc. Press Release • July 29, 2021
AZTherapies announced that its Phase 3 COGNITE trial of ALZT-OP1 in early Alzheimer's disease did not meet its co-primary efficacy endpoints. The company stated it would continue to analyze the data to understand the results fully....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AZTherapies, are just a search away.